RBF Capital LLC Has $8.43 Million Stock Holdings in The Chemours Company (NYSE:CC)

RBF Capital LLC grew its holdings in The Chemours Company (NYSE:CC - Free Report) by 42.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 414,618 shares of the specialty chemicals company's stock after purchasing an additional 124,311 shares during the quarter. RBF Capital LLC owned 0.28% of Chemours worth $8,425,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CC. Price T Rowe Associates Inc. MD boosted its holdings in shares of Chemours by 3.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 91,345 shares of the specialty chemicals company's stock valued at $2,399,000 after acquiring an additional 2,932 shares during the period. Linden Thomas Advisory Services LLC acquired a new stake in shares of Chemours in the 2nd quarter valued at approximately $460,000. SG Americas Securities LLC purchased a new position in shares of Chemours in the 2nd quarter valued at about $529,000. Twelve Points Wealth Management LLC grew its position in Chemours by 15.7% during the second quarter. Twelve Points Wealth Management LLC now owns 22,548 shares of the specialty chemicals company's stock worth $509,000 after buying an additional 3,068 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Chemours during the 2nd quarter valued at approximately $2,504,000. Institutional investors and hedge funds own 76.26% of the company's stock.

Insider Activity

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the transaction, the senior vice president now directly owns 16,645 shares in the company, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.47% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group lowered their price objective on shares of Chemours from $29.00 to $23.00 and set a "neutral" rating on the stock in a research note on Tuesday, September 3rd. BMO Capital Markets raised their price objective on Chemours from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, October 7th. Royal Bank of Canada cut their target price on shares of Chemours from $28.00 to $25.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Morgan Stanley cut their price objective on Chemours from $30.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 5th. Finally, Barclays raised their target price on Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $24.88.

Chemours Price Performance

Shares of Chemours stock traded down $0.53 during trading on Thursday, hitting $20.75. 435,716 shares of the company's stock traded hands, compared to its average volume of 1,563,375. The Chemours Company has a twelve month low of $15.10 and a twelve month high of $32.70. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The company has a market cap of $3.10 billion, a PE ratio of 42.56 and a beta of 1.80. The firm's fifty day moving average price is $19.86 and its 200 day moving average price is $21.14.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. During the same quarter last year, the company earned $0.64 EPS. Chemours's revenue was up .9% on a year-over-year basis. Analysts forecast that The Chemours Company will post 1.35 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.00 annualized dividend and a yield of 4.82%. Chemours's dividend payout ratio is 200.00%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.